|
Investors |
Lotus Pharmaceuticals Inc. provides investors an opportunity to gain exposure to the Chinese pharmaceuticals market. Pharmaceutical sales in China have grown at average annual rate of 14 percent for the past 15 years. The total market stood $10 billion USD in 2005.
In China alone, it is estimated that more than 160 million patients suffer from hypertension, and more than 20 million have diabetes. Millions of patients will rely on VALSARTAN to help them improve their health and maintain healthier blood pressure goals. Now, based on results from one of the largest mega trial programs in the ARB class,VALSARTAN has demonstrated additional benefits that can address the needs of an even broader spectrum of cardiovascular patients.
We aspire to responsible and conscientious global citizenship based on trust, transparency and accountability. The buttress of our commitment is to participate in a global culture in areas where we are competent, helping where needed most, while also establishing and implementing transparent, ethical corporate standards and policies. |
|
| This website contains forward-looking statements that involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the company's limited operating history, the limited financial resources, domestic or global economic conditions -- especially those relating to China, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws, restrictions and regulations on doing business in a foreign country, in particular China, and conditions of equity markets. More information about the potential factors that could affect the company's business and financial results is included in the Company's filings, available via the United States Securities & Exchange Commission. Occasionally, the Company may select and post articles or opinions of third parties, with no known connection with the Company. These are considered expert or qualified writers about the Chinese economy and its various opportunities and pitfalls. The Company neither endorses nor rejects these views or content, and the articles are offered only for the readers' edification and personal analyses. |
|
